mdm-2 oncogene expression in non-Hodgkin's lymphomas

Diagnostic Molecular Pathology

Volumn 5, Issue 1, 1996, Pages 33-38

  Kawamata, Norihiko ^a   Miller, Carl ^a   Levy, Veronica ^a   Shintaku, I Peter ^a   Koeffler, H Phillip ^a   Said, Jonathan W ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Malignant lymphoma; mdm 2; p53

Indexed keywords

GENE PRODUCT;

ARTICLE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SOUTHERN BLOTTING;

BLOTTING, SOUTHERN; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030032584     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-199603000-00006     Document Type: Article

References (26)

1. Bueso-Ramos C, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human mdm-2 oncogene is overexpressed in leukemias. Blood 1993;82:2617-23.
2. Cesarman E, Liu F, Knowles DM. The mdm-2 oncogene is rarely amplified in human lymphoid tumors and does not correlate with p53 expression [Letter]. Int J Cancer 1994;56:457-8.
3. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13:4107-14.
4. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
5. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993;13:301-6.
6. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
7. Ho J, Shintaku IP, Preston M, Said JW. Can microwave antigen retrieval replace frozen section immunohistochemistry in the phenotyping of lymphoid neoplasms? Appl Immunohistochem 1994;2:282-6.
8. Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, Krolewski J. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 1994;145:287-93.
9. Kessis TD, Siebos RJ, Han SM, et al. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol 1993;143:1398-405.
10. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 1993;53:5535-41.
11. Matsushima A, Cesarman E, Chadburn A, Liu J, Knowles DM. p53 protein overexpression frequently occurs but p53 gene mutations infrequently occur in post thymic T cell lymphomas. Mod Pathol 1993;6:95A.
12. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53- mediated transactivation. Cell 1992;69:1237-45.
13. Nakamura H, Said JW, Miller CW, Koeffler HP. Mutation and protein expression of p53 in AIDS-related lymphomas. Blood 1993;82:920-6.
14. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80.
15. Pinkus GS, O'Hara CJ, Said JW. Peripheral/post thymic T cell lymphomas: a spectrum of disease-clinical, pathologic, and immunologic features of 78 cases. Cancer 1990;65:971-98.
16. Pinkus GS, Pinkus JL, Goldstein NS, Shintaku IP, Said JW. BLA.36 A putative marker for B cell proliferations-staining profile of 426 paraffin-embedded tissues. Appl Immunohistochem 1995;3:23-31.
17. Pinkus GS, Said JW. Characterization of non-Hodgkin's lymphomas using multiple cell markers: immunologic, morphologic and cytochemical studies of 72 cases. Am J Pathol 1979;94:349-76.
18. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-9.
19. Ridge AS, Dyer M, Greaves MF, Weidemann LM. Lack of MDM2 amplification in human leukemia. Br J Haematol 1994;86:407-9.
20. Saez GT, Oliva MR, Mangues R, Pellicer A. Absence of MDM-2 gene amplification in experimentally induced tumors regardless of p53 status. Mol Carcinog 1994;9:40-5.
21. Said JW, Barrera R, Shintaku IP, Nakamura H, Koeffler P. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol 1992;141:1343-8.
22. Szpirer J, Szpirer C, Riviere M, et al. The Spl transcription factor (SP1) and the 1,25-dihydroxyvitamin D3 receptor gene (VDR) are colocalized on human chromosome arm 12q and rat chromosome 7. Genomics 1991;11:168-73.
23. Walts AE, Koeffler HP, Said JW. Localization of p53 protein and human papillomavirus in anogenital squamous lesions: immunohistochemical and in situ hybridization studies in benign, dysplastic, and malignant epithelia. Hum Pathol 1993;24:1238-42.
24. Walts AE, Said JW, Koeffler HP. Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localization of p53 gene product in benign mesothelial and adenocarcinoma cells. Mod Pathol 1994;7:462-8.
25. Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 onco-gene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158-65.
26. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.